ADIL Adial Pharmaceuticals, Inc.

29

Healthcare [ 5/11 ] | Biotechnology [ 53/112 ]

US | NASDAQ | Stock

Price
$0.275
Increased by +0.05%
Dollar Volume (20D)
38.90 K
ADR%
9.56
Earnings Report Date (estimate)
Aug 14, 23 (0.06)
Market Cap.
7.84 M
Shares Float
5.30 M
Shares Outstanding
28.52 M
Beta
0.95
Price / Earnings
-0.54
BPR
45.24
20D Range
0.24 0.36
50D Range
0.24 0.46
200D Range
0.20 0.61
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
May 15, 23 -0.11
Increased by +31.25%
 -0.14
Increased by +153.06%
May 12, 23 -0.11
Increased by +31.25%
 -0.14
Increased by +153.06%
Mar 30, 23 -0.11
Increased by +15.38%
 -0.15
Increased by +177.78%
Nov 14, 22 -0.12
Increased by +57.14%
 -0.18
Increased by +185.19%
Aug 16, 22 -0.16
Increased by +27.27%
 -0.14
Decreased by -102.04%
Aug 15, 22 -0.16
Increased by +36.00%
 -0.14
Decreased by -102.04%
May 16, 22 -0.13
Increased by +45.83%
 -0.17
Increased by +138.41%
Mar 28, 22 -0.28
Decreased by -16.67%
 -0.21
Decreased by -158.73%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 23 0.00
Decreased by N/A%
 -2.89 M
Decreased by -4.87%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0.00
Decreased by N/A%
 -2.87 M
Increased by +52.37%
Decreased by N/A%
Decreased by N/A%
Sep 30, 22 0.00
Decreased by N/A%
 -3.03 M
Increased by +29.80%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
 -3.86 M
Increased by +12.98%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
 -2.76 M
Increased by +42.97%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
 -6.02 M
Decreased by -73.50%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
 -4.32 M
Decreased by -29.44%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
 -4.44 M
Decreased by -145.21%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.